Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from GlaxoSmithKline.

Advances In™ Pathology: Understanding the Rationale for PARP Inhibitors Across Solid Tumors

Release Date: March 15, 2021
Expiration Date: March 15, 2022

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the use of poly(ADP-ribose) polymerase (PARP) inhibitors across several different solid tumor types, with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of molecular testing, clinical trial data, current and emerging treatment strategies, and management of treatment-related toxicities will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward pathologists involved in the treatment of patients with cancer. Other health care professionals involved in the diagnosis and treatment of cancer will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Assess recent clinical trial data that inform the current and upcoming role of PARP inhibitors in treating solid tumors
  • Describe diagnostic testing strategies that guide the use of PARP inhibitor therapy
  • Integrate available data regarding PARP inhibitor therapy into clinical scenarios

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Bradley J. Monk, MD, FACS, FACOG
Bradley J. Monk, MD, FACS, FACOG
Professor and Director, Division of Gynecologic Oncology
Creighton University School of Medicine at St. Joseph's Hospital and Medical Center
Professor on the Clinical Scholar Track
University of Arizona College of Medicine
Physician, Arizona Oncology (US Oncology Network)
Medical Director of Gynecologic Oncology Research, US Oncology
Co-director, GOG-Partners
Member, Board of Directors, GOG-Foundation
Phoenix, AZ

Disclosures: Consultant: AbbVie, Agenus, AkesoBio, Aravive, AstraZeneca, Clovis Oncology, Eisai, Genmab/Seattle Genetics, GOG Foundation, ImmunoGen, Iovance Biotherapeutics, Merck, Mersana Therapeutics, Myriad Genetics, Pfizer, Puma Biotechnology, Roche/Genentech, Starton Therapeutics, Tesaro/GlaxoSmithKline, Vavotar Life Sciences, VBL Therapeutics; Speakers Bureau: AstraZeneca, Clovis Oncology, Eisai, Merck, Roche/Genentech, Tesaro/GlaxoSmithKline.

Timothy A. Yap, MBBS, PhD, FRCP
Timothy A. Yap, MBBS, PhD, FRCP
Associate Professor, Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine
Medical Director, The Institute for Applied Cancer Science
Associate Director of Translational Research, Khalifa Institute for Personalized Cancer Therapy
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Research support (to Institution): Artios, AstraZeneca, Bayer, Clovis, Constellation, Cyteir , Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, Ipsen, Jounce, Karyopharm, Kyowa, Merck, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, and Vertex Pharmaceuticals. Consultancies: Almac, Aduro, AstraZeneca, Atrin, Axiom, Bayer, Bristol Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, Guidepoint, Ignyta, I-Mab, Jansen, Merck, Pfizer, Repare, Roche, Rubius, Schrodinger, Seattle Genetics, Varian and Zai Labs.

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By